Our healthcare system is extremely complicated, with a lot of moving parts, but is nevertheless one of our most important economic drivers. Within this industry, a new product must face complex restrictions and the attention of a variety of different parties. Before a solution to the patient’s problem may be presented, it has to face a complex path from the scientist at one end to the sufferer at the other. In the dissemination of information, pharmaceutical consultants help to ensure that all those who have an input into the decision-making process are fully aware of all the repercussions.
A pharmaceutical company faces many challenges, quite apart from the manufacture of its products. As a pharmaceutical consulting firm stresses, the company owes the consumer in general a debt of revelation. Most often, the pharmaceutical companies are at the cutting-edge of science and help to uncover solutions or possibilities previously unheard-of. If they have not paid sufficient attention to marketing, all the exploratory work may fail as the path through the regulators to the professionals may seem unclear. Marketing also insists that the product features and benefits are correctly communicated to the financiers, principally the insurance companies, who seem to have an ever-increasing role in the dissemination of care.
While regulators will ultimately determine if a pharmaceutical product may be made available and will confirm the associated claims, the pharmaceutical company must be able to market itself, its reputation and its products within the ultra-competitive and distracted healthcare industry. It should be noted that certain principals within the industry have an incentive to steer healthcare practitioners and their patients toward older, or generic medications and that these agendas may not be in the best interests of the sufferer. Pharmaceutical companies must create a position within such a difficult marketplace, in order to push science and discovery and their own significant position forward.
It is unfortunate that the ultimate care of the patient is very often not the ultimate goal of certain vested interests. While healthcare reform and especially its associated finances remain a hot button issue, the pharmaceutical company must do everything in its power to ensure that its lines of communication are open. The physician takes input from many different sources before he or she makes the decision as to final care, including experience, peer input, education and training, patient history, formularies, techniques and benchmarks – all play their role. If you consider that nine out of ten most frequently prescribed drugs are generics, it should be clear that far from being in a position of dominance, pharmaceutical companies must make every effort to ensure that their marketing messages are heard. Generally, pharma consulting firms play their part in helping to establish channels and best practices.
Many of the most striking advances in the dissemination of medicine in recent years have been a result of work by pharmaceutical companies. Cures that would have been unheard-of a generation ago are now commonplace. Much emphasis must be put on marketing “the word” to ensure that our health care continues to improve.
Alan Gillies is the Managing Director of L2L Consulting, specialising in enabling pharmaceutical companies to achieve new heights of productivity and performance, throughout all levels of management and revenue generating activities.
